GI Innovation-Panoros Collaborate on Development of 'Next-Generation Multi-Target Therapeutics'

GI Innovation announced on the 28th that it has signed a joint research memorandum of understanding (MOU) with Panoros Biosciences for the development of next-generation multi-target therapeutics.

Hong Junho, CEO of GI Innovation (left), and Im Hyesung, CEO of Panoros Biosciences, are posing for a commemorative photo at the signing ceremony.
[Photo by GI Innovation]

The signing ceremony, held on the 27th at GI Innovation's headquarters in Songpa-gu, Seoul, was attended by key executives from both companies, including Jang Myung-ho, Chief Strategy Officer (CSO) of GI Innovation, CEO Hong Jun-ho, Panoros CEO Lim Hye-sung, and Chief Business Officer (CBO) Jo Young-hoon. Through this MOU, the two companies plan to collaborate with goals including ▲mutual technology exchange ▲non-clinical and clinical development ▲global technology transfer ▲selection for national research and development (R&D) projects.

GI Innovation is a company specializing in the development of immune-oncology drugs based on bispecific fusion proteins, conducting clinical trials for immune-oncology and allergy therapeutics using its GI-Smart platform technology. Panoros is a structure-based protein drug development company currently conducting clinical trials for PB101, which has anti-tumor immune system enhancement and vascular normalization functions. Both companies expect various synergies based on their proprietary protein development technologies.

Hong Jun-ho, CEO of GI Innovation, stated, “We expect synergy from multifaceted research through the combination of Panoros’s alphaART platform and GI Innovation’s GI-Smart platform,” adding, “We hope this MOU will further activate research exchanges among domestic bio ventures.” Lim Hye-sung, CEO of Panoros, also said, “We expect this agreement to be an important turning point in combining the expertise and capabilities of both companies to develop new treatment methods and innovative solutions.”

This content was produced with the assistance of AI translation services.